Suggestions
Amir Hayeri
CEO @ Bio Conscious Tech
Amir Hayeri is a visionary entrepreneur, innovator, and accomplished software engineer based in Vancouver. As the CEO and founder of Bio Conscious Technologies Inc., he leads a groundbreaking health technology startup focused on revolutionizing preventative care for chronic conditions through AI-powered solutions.
Bio Conscious Technologies' flagship product, Endobits, is a pioneering platform that transforms the management and prevention of diabetes complications. By leveraging machine-learning technology, Endobits empowers healthcare providers and patients to proactively address high-risk glycemic events, leading to enhanced health outcomes supported by numerous clinical studies.
Amir's exceptional leadership and innovation have garnered prestigious accolades, including being named 'Healthcare CEO of the Year- Canada' and 'Most Innovative CEO of the Year- Canada' at the Business World Magazine's CEO Awards. Additionally, his commitment to excellence was recognized with the 'IBM Design Award for Best App for Patients' in 2016.
An esteemed member of the Forbes Technology Council since 2020, Amir is a respected industry expert and a featured contributor on Forbes.com. Through his insightful contributions, Amir shares his profound knowledge on the intersection of machine learning and life sciences, the impacts of glucose metabolism on aging, and the impending AI singularity.
For collaborations with Bio Conscious Technologies or to connect with Amir Hayeri, inquiries can be directed to [email protected].
Highlights
Being a pioneer in any industry can at times be a lonely experience, and so it’s great to see others in the health care community work to expand Remote Patient Monitoring services. My company, Bio Conscious, has been working tirelessly to grow this emerging space with our Endobits solution. Endobits is an example of the practical application of Artificial Intelligence to enhance the clinicians' capacity to manage the ever increasing flood of data. Currently my team is focused on glucose and providing decision-support to clinicians to truly make a difference in the treatment and management of diabetes. In the coming years, I envision a world where Bio Conscious delivers AI-powered solutions to help clinicians deliver care across multiple chronic disease states deliver care across multiple chronic disease states. Check out this article from Science Direct that touches on this theme.
https://lnkd.in/gU59vD_D
The Dexcom Stelo: A Game Changer in Diabetes Care
Today, Dexcom launched its latest CGM, the over-the-counter Stelo (www.stelo.com), which promises to enhance the user experience and improve diabetes management. This innovative device offers several key features:
- Real-Time Monitoring: The Stelo provides real-time glucose data every five minutes, allowing users to respond quickly to fluctuations in their glucose levels.
- User-Friendly Design: With a sleek design and intuitive mobile app, the Stelo prioritizes ease of use for all age groups, ensuring that even those new to diabetes management can navigate its features effectively.
- Integration with Smart Devices: The Stelo seamlessly integrates with smartphones, wearables, and insulin delivery systems, enabling a connected ecosystem that simplifies diabetes management.
- Improved Accuracy: Dexcom's new sensor technology offers enhanced accuracy, which is crucial for making informed treatment decisions. Studies show that accurate glucose readings can reduce the risk of hypoglycemia and hyperglycemia.
That's only HALF the story. Once you have a CGM then you need it to be able to talk to your doctor's office - that's where we come in with ENDOBITS. Our easy-to-use software helps clinicians better manage diabetes care for their patients using industry-leading AI. We are one of the pioneers in the Remote Patient Monitoring category and we are pushing everyday to educate clinicians and patients about the best ways to work together to improve the overall management of healthcare
Why do I think the further adoption of CGM's is critical to the future of diabetes care --
- According to a study published in Diabetes Care, users of CGMs experienced a significant reduction in HbA1c levels—an average decrease of 0.5% to 1.0%—compared to those relying solely on fingerstick testing.
- Research indicates that CGM users also report fewer instances of hypoglycemic events, with one study showing a 38% reduction in severe hypoglycemic episodes.
- The American Diabetes Association states that effective diabetes management can reduce the risk of complications by up to 30% when utilizing advanced technologies like CGMs.
#dexcom #stelo #cgm #aihealthcare
